Aquinox Pharmaceuticals, Inc. (AQXP) Company Profile
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.
News about AQXP
Somewhat Positive Press Coverage Somewhat Unlikely to Impact Aquinox Pharmaceuticals (AQXP) Stock Pr
From:www.tickerreport.com
Media coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sourc...Read More>>>
Aquinox Pharmaceuticals (AQXP) Downgraded to “Sell” at ValuEngine
From:www.tickerreport.com
Aquinox Pharmaceuticals (NASDAQ:AQXP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday.
AQXP has been the subject of several other reports. Cantor Fitzgerald...Read More>>>
Aquinox Pharmaceuticals (AQXP) Given Neutral Rating at Cantor Fitzgerald
From:www.tickerreport.com
Cantor Fitzgerald reiterated their neutral rating on shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) in a research report report published on Wednesday, MarketBeat.com reports.
“: We are downgrading our opinion of AQXP stock from and we are l...Read More>>>
Why Sonic, National Beverage, and Aquinox Pharmaceuticals Slumped Today
From:www.fool.com
Stocks declined on Wednesday as investors continued to worry about U.S. trade policy, but not before attempting to rally earlier in the session after President Trump announced plans to update existing laws to limit or prevent investments by China in ...Read More>>>
Ambev, Starbucks Drop into Wednesday’s 52-Week Low Club
From:247wallst.com
June 27, 2018: Here are four stocks trading with heavy volume among 157 equities making new 52-week lows in Wednesday’s session. On the NYSE decliners led advancers by about 2.38 to 1 and on the Nasdaq, advancers led decliners by about 3.95 to ...Read More>>>
